Concepedia

Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials

Remo Panaccione, Brian G. Feagan, Anita Afzali, David T. Rubin, Walter Reinisch, Julián Panés, Silvio Danese, Tadakazu Hisamatsu, Natalie A. Terry, Leonardo Salese,

The Lancet · 2025 · 37 citations · 12 references

DOIFull text

Open access

Concepts

References

12

ACG Clinical Guideline: Management of Crohn's Disease in Adults

Gary R. Lichtenstein, Edward V. Loftus, Kim L. Isaacs et al. · The American Journal of Gastroenterology · 2018 · 1.4K citations

, , +12

ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment

Hannah Gordon, Silvia Minozzi, Uri Kopylov et al. · Journal of Crohn s and Colitis · 2024 · 315 citations · Full text

, , +16

Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study

William J. Sandborn, Geert D’Haens, Walter Reinisch et al. · Gastroenterology · 2022 · 198 citations · Full text

, , +17

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

Laurent Peyrin‐Biroulet, J. Casey Chapman, Jean‐Frédéric Colombel et al. · New England Journal of Medicine · 2024 · 160 citations · Full text

, , +13

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

Marc Ferrante, Julien Fahed · The Lancet · 2024 · 102 citations · Full text

, , +11